Ep. 252, Chapter 5: From Rare To Large Indications

43:25 - End

While Alnylam is well-equipped for rare and specialty conditions, broader public health issues such as hypertension and, potentially, Alzheimer’s, necessitate a shift in company mindset and a different commercialization approach. Alnylam’s strategic partnership with Roche for Zilebesiran will leverage the latter’s experience in CNS conditions and help to build Alnylam's capabilities for future large-scale opportunities. For 2025, Alnylam's top priorities include the launch of Amvuttra for cardiomyopathy and strengthening the company’s foundational commercial capabilities, such as AI, data generation, value-based agreements, and omnichannel marketing.